PUBLISHER: KuicK Research | PRODUCT CODE: 1529409
PUBLISHER: KuicK Research | PRODUCT CODE: 1529409
Global CRISPR Cas9 Market Opportunity & Clinical Trials Outlook 2029
Global CRISPR Cas9 Market Opportunity & Clinical Trials Outlook 2029 Report Offering:
- Global & Regional: Commercial & Clinical Outlook
- Global CRISPR-Cas9 Therapy Clinical Trials By Company, County, Indication & Phase
- Number Of CRISPR-Cas9 Therapies In Trials: > 25 Therapies
- Approved CRISPR-Cas9 Therapy: Casgevy (Exagamglogene Autotemcel) Therapy Clinical Insight
- Approved CRISPR-Cas9 Therapy Pricing & Dosing Analysis
- Technology Platforms For Advancing CRISPR-Cas9 Therapy
- Delivery Methodologies For CRISPR-Cas9
- Competitive Landscape
Antecedently, out-of-date bestseller conventional therapies, including chemotherapy or targeted therapies, were utilized for the management of cancer, autoimmune, inflammation and other diseases; yet, clinical researchers were occupied tenaciously with the hypothesis of discovering other cutting edge technologies. The growing rampant of genetic disorders across the globe at a frightening gait as well as the need for an effective cure has led to the discovery of CRISPR/Cas9 therapy. Build on the triumph of gene therapies, these therapies clenches gargantuan plausibility with only one CRISPR/Cas9 therapy; Casgevy, approved into the commercial market, as of July 2024, to treat sickle cell anemia along with beta thalassemia and is currently accessible in US, EU, UK, Saudi Arabia and Bahrain; proposing novel opportunity in the approaching years.
With respect to KuicK Research statistics, we anticipate to perceive the first wave of CRISPR/Cas9 therapies receiving regulatory approvals over and above entering the market in upcoming 5 years due to the fact that as these therapies demonstrate their effectiveness in addition to safety in real-world settings, they will pave the way for broader acceptance and application of CRISPR/Cas9 based treatments. Coupled with this, the potential applications of this groundbreaking gene-editing technology are expected to expand dramatically beyond genetic disorders and cancers and will be utilized to cure cardiovascular, neurodegenerative together with CNS diseases as evident from rising preclinical as well as clinical studies, touching fundamentally every area of medicine and biotechnology.
Until now, the clinical pipeline for global CRISPR/Cas9 therapy is up surging year by year with multiple therapies have entered into clinical trials and other CRISPR/Cas9 candidates are lately in the preclinical stage. Many of ongoing CRISPR/Cas9 clinical trials have reached late stage of development and it is predicable that they will penetrate into the market in the imminent 5-7 years. For instance, Intellia Therapeutics has begun a phase III, multinational, multicenter, double-blind, placebo-controlled study is ongoing which aims to evaluate the efficacy and safety of a single dose of NTLA-2001, a CRISPR/Cas9 therapy, compared to placebo in participants with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The study (MAGNITUDE) was begun in December 2023 and is anticipated to be complete by April 2028 coupled with clenches an enrollment of 765 participants.
Just as importantly, the over-all market for CRISPR/Cas9 therapies is estimated to grow substantively and will become a multi-billion-dollar industry over the impending eons, driven by the snowballing number of preclinical and clinical trials, the likely regulatory approvals, in conjugation with the increase of indications. Currently, the US dominates the CRISPR/Cas9 sphere in terms of research and development activities, but EU is correspondingly far-sighted momentous evolution in this field.
As well as, the current approved CRISPR/Cas9 therapy; Casgevy, developed by CRISPR Therapeutics and Vertex Pharmaceutical, is launched into the market at an average cost of roughly US$ 2 Million per single course of treatment according to Casgevy developer company SEC filings. Additionally, the anticipated high prices of these therapies, justified by their potential curative nature, are expected to further drive significant market growth in terms of revenue, even with relatively small patient populations.
As a final point, all elucidations aforesaid epitomize that the global CRISPR/Cas9 therapy is growing at a trailblazing gait and is predictable to multiply additional in the forthcoming 10 years. The expanding clinical application as well as together with indication of CRISPR/Cas9, mounting preclinical and clinical trials, rise in technological advancement, presences of key players like Intellia Therapeutics, CRISPR Therapeutics, Editas Medicine, TransCode Therapeutics and many more, combination studies of CRISPR/Cas9 with other therapies coupled with augment in investment, collaborations and government bestow are driving the market penetration, offering opportunism to pharma and biotech companies in future.
Table of Contents
1. Synopsis To CRISPR-Cas9 Therapy
- 1.1 Overview
- 1.2 Approved CRISPR-Cas9 Therapies
2. Delivery Methods For CRISPR-Cas9
- 2.1 Delivery of CRISPR-Cas9 Components Through Physical Methods
- 2.1.1 Microinjection
- 2.1.2 Electroporation
- 2.1.3 Hydrodynamic Delivery
- 2.2 Delivery of CRISPR-Cas9 Components through Viral Vectors
- 2.2.1 Adeno-Associated Virus (AAV)
- 2.2.2 Lentivirus & Adenovirus
- 2.3 Delivery of CRISPR-Cas9 Components through Non-Viral Vectors (Biomaterials)
- 2.3.1 Liposomes
- 2.3.2 Gold Nanoparticles
- 2.3.3 DNA Nanoclew
3. CRISPR-Cas9: A Home To Variety Of Applications
- 3.1 Advantages Accompanying CRISPR-Cas9 Technology
- 3.2 CRISPR-Cas9 Comparison with other Genome Editing Tools
4. Global CRISPR-Cas9 Therapy Clinical Trials Overview
- 4.1 By Company
- 4.2 By Country
- 4.3 By Indication
- 4.4 By Phase
- 4.5 By Priority Status
5. Global CRISPR-Cas9 Therapy Clinical Trials By Company, County, Indication & Phase
- 5.1 Research
- 5.2 Preclinical
- 5.3 Phase I
- 5.4 Phase I/II
- 5.5 Phase II
6. Approved CRISPR - Cas9 Therapy: Casgevy (Exagamglogene Autotemcel) Therapy Clinical Insight
7. Approved CRISPR-Cas9 Therapy - Overview, Pricing & Dosing Analysis
- 7.1 Casgevy (Exagamglogene Autotemcel)
- 7.1.1 Overview
- 7.1.2 Pricing & Dosing
8. Global CRISPR-Cas9 Therapy Current Market Trend & Developments
- 8.1 Current Market Outline
- 8.2 Future Market Outlook
9. CRISPR-Cas9 Therapy Market Trend Analysis By Region
- 9.1 US
- 9.2 UK
- 9.3 EU
- 9.4 China
- 9.5 Japan
- 9.6 South Korea
10. CRISPR-Cas9 Therapy Market Opportunities & Clinical Trial Statistics: By Indications
- 10.1 Inherited Blood Disorders
- 10.2 Genetic Disorders
- 10.3 Cancer
- 10.4 Autoimmune & Inflammatory Disorders
- 10.5 Microbial Infections
- 10.6 Cardiovascular Illnesses
- 10.7 Eye Disorders, Brain Diseases, Metabolic Illness & Other Conditions
11. Combination Approaches For CRISPR-Cas9 Therapy
12. Platforms For Advancing CRISPR-Cas9 Therapy
- 12.1 CRISPR-GNDM Modalis Therapeutics Platform
- 12.2 Intellia Therapeutics - Modular Platform
- 12.3 Editas Medicine CRISPR Gene Editing Platform
- 12.4 CRISPR-Cas9 Genome Editing Technology - ERS Genomics
- 12.5 CRISTARS Gene Editing Technology Innovation Platform- BRL Medicine
- 12.6 Gene Editing-BDmRNA Platform Shanghai BDgene
- 12.7 Kamau Therapeutics Next-Generation Gene Editing Platform
- 12.8 Excision BioTherapeutics CRISPR Gene Editing Technology
13. Global CRISPR-Cas9 Therapy Market Dynamics
- 13.1 Market Drivers
- 13.2 Market Achilles Heels
14. Competitive Landscape
- 14.1 4D Molecular Therapeutics
- 14.2 Arbor Biotechnologies
- 14.3 ASC Therapeutics
- 14.4 C4U Corporation
- 14.5 Casebia Therapeutics
- 14.6 CRISPR Therapeutics
- 14.7 Editas Medicine
- 14.8 Intellia Therapeutics
- 14.9 Nkarta Therapeutics
- 14.10 Vertex Pharmaceuticals
List of Tables
- Table 1-1: Global - Approved CRISPR-Cas9 Therapies
- Table 9-1: US - Ongoing CRISPR-Cas9 Clinical Trials
- Table 9-2: CRISPR-Cas9 Candidates Granted FDA Designations
- Table 9-3: EU - Ongoing Clinical Trials for CRISPR/Cas9-based Therapeutics, July'2024
- Table 9-4: ERS Genomics - Collaborations
- Table 10-1: Ongoing CRISPR-Cas9 Clinical Trials for Inherited Blood Disorders
- Table 10-2: Ongoing CRISPR-Cas9 Clinical Trials for Cancer Disorders
- Table 10-3: Collaboration Deals For Cancer CRISPR-Cas9 Therapy, July 2024
- Table 11-1: Ongoing Preclinical & Clinical trials for Combination of CRISPR-Cas9 Therapy
List of Figures
- Figure 1-1: CRISPR-Cas9 Therapy v/s Conventional Therapies
- Figure 2-1: Delivery Methods for CRISPR-Cas9
- Figure 2-2: Delivery Pathways for CRISPR-Cas9 Components
- Figure 2-3: Physical Mode of Delivery for CRISPR-Cas9 Components
- Figure 2-4: Viral Mode of Delivery for CRISPR-Cas9 Components
- Figure 2-5: Non-Viral Mode of Delivery for CRISPR-Cas9 Components
- Figure 3-1: Advantages of CRISPR-Cas9 Technology
- Figure 3-2: Comparison between Different Genome Editing Tools
- Figure 4-1: Global - CRISPR-Cas9 Therapy Clinical Trials by Company (Number of Drugs), 2024 till 2029
- Figure 4-2: Global - CRISPR-Cas9 Therapy Clinical Trials by Country (Number of Drugs), 2024 till 2029
- Figure 4-3: Global - CRISPR-Cas9 Therapy Clinical Trials by Indication (Number of Drugs), 2024 till 2029
- Figure 4-4: Global - CRISPR-Cas9 Therapy Clinical Trials by Phase (Number of Drugs), 2024 till 2029
- Figure 4-5: Global - CRISPR-Cas9 Therapy Clinical Trials by Priority Status (Number of Drugs), 2024 till 2029
- Figure 7-1: Casgevy - Approval Year by Region
- Figure 7-2: Casgevy - Patent Expiration Year, July'2024
- Figure 7-3: US - Cost per Treatment of Casgevy (US$ in Million), July'2024
- Figure 8-1: Global CRISPR-Cas9 Therapy - Important Companies
- Figure 8-2: Dominating & Emerging Region in Global CRISPR-Cas9
- Figure 8-3: CRISPR-Cas9 - Future Market
- Figure 8-4: Global - CRISPR Cas9 Market Opportunity (US$ Million), 2024 -2029
- Figure 9-1: CRISPR_SCD001 Phase I/II (NCT04774536) Study - Initiation & Completion Year
- Figure 9-2: Intellia Therapeutics - In vivo & Ex vivo CRISPR Approach
- Figure 9-3: Crucial US CRISPR-Cas9 Competitor
- Figure 9-4: EBT-101 Phase I (NCT05144386) Study - Initiation & Completion Year
- Figure 9-5: NTLA-2002 Phase I/II (NCT05120830) Study - Initiation & Completion Year
- Figure 9-6: EU Major Hubs in CRISPR-Cas9 Therapy
- Figure 9-7: BRL-101 Phase I (NCT06300723) Study - Initiation & Completion Year
- Figure 9-8: ET-01 Phase I (NCT04925206) Study - Initiation & Completion Year
- Figure 9-9: GRIT Biotechnology Clinical Pipeline
- Figure 9-10: GT307 (NCT06453057) Study - Initiation & Completion Year
- Figure 9-11: CRISPR-Cas9 - Key Players in China
- Figure 9-12: Aspects Influencing Japanese CRISPR-Cas9 Market
- Figure 9-13: Modalis Therapeutics & JCR Pharmaceuticals Collaboration
- Figure 9-14: ToolGen's TGT-001 - Orphan Drug Designation
- Figure 10-1: BRL-101 Phase I (NCT06287086) Study - Initiation & Completion Year
- Figure 10-2: Acquisition of Graphite Bio Lead Candidate & CRISPR-Cas9 Platform by Kamau Therapeutics
- Figure 10-3: Nula-cel Phase I/II (NCT04819841) Study - Initiation & Completion Year
- Figure 10-4 REGV131-LNP1265 Phase I/II (NCT06379789) Study - Initiation & Completion Year
- Figure 10-5: Sanofi & Scribe Therapeutics Collaboration
- Figure 10-6: Discovery of Innovative CRISPR-Cas9 Approach by University of Trento
- Figure 10-7: National Institutes of Health Grants for CRISPR-Cas9 Therapy
- Figure 10-8: NTLA-2001 Phase I (NCT04601051) Study - Initiation & Completion Year
- Figure 10-9: NTLA-2001 Phase III MAGNITUDE (NCT06128629) Study - Initiation & Completion Year
- Figure 10-10: Commercial Genetic Disorder CRISPR-Cas9 Therapy Market Overview
- Figure 10-11: CRISPR-Cas9 Approaches To Cure Cancer
- Figure 10-12: CRISPR-Cas9 Combinations with Cryotherapy & Others For Cancer Treatment
- Figure 10-13: CTX112 Phase I/II (NCT05643742) Study - Initiation & Completion Year
- Figure 10-14: MEDiC Life Sciences Collaboration with Bristol Myers Squibb (BMS) on Tumor Target Discovery
- Figure 10-15: Innovative Genomics Institute Gene Correction Strategy for Autoimmune Patients
- Figure 10-16: BDgene Reported Optimistic Phase I Outcomes of BD111
- Figure 10-17: CRISPR Therapeutics Pipeline
- Figure 10-18: BD113vLVP (NCT06465537) Study - Initiation & Completion Year
- Figure 10-19: ZVS203e Phase I (NCT05805007) Study - Initiation & Completion Year
- Figure 10-20: Editas Medicine CRISPR-Cas9 Therapies Synopsis
- Figure 10-21: EDIT-101 Phase I/II (NCT03872479) Study - Initiation & Completion Year
- Figure 10-22: SNIPR Biome - CRISPR-Cas9 Engineered Microbial Gene Therapy For Various Indications
- Figure 12-1: CRISPR-GNDM Modalis Therapeutics Platform
- Figure 12-2: Advantage of CRISPR-GNDM
- Figure 12-3: Editas Medicine - CRISPR Gene Editing Platform
- Figure 12-4: Gene Editing Technology Innovation Platform (CRISTARS) - BRL Medicine
- Figure 12-5: Gene Editing-BDmRNA Platform - BDgene
- Figure 12-6: Kamau Therapeutics Next Generation Gene Editing Platform
- Figure 12-7: Excision's CRISPR Approach
- Figure 12-8: Excision BioTherapeutics CRISPR Gene Editing Technology
- Figure 13-1: CRISPR-Cas9 Therapy - Market Drivers
- Figure 13-2: CRISPR-Cas9 - Market Challenges
